Victor Schweiger

Victor Schweiger

Auto-generated profile, based on publicly available information

Victor Schweiger

Department of Cardiology, Angiology and Intensive Care Medicine Deutsches Herzzentrum der Charité Berlin Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2024 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
BSBarbara E. Stähli
Barbara E. Stähli
MSMatthias Schindler
Matthias Schindler
VSVictor Schweiger
Victor Schweiger
VCVictoria L. Cammann
Victoria L. Cammann
KSKonrad A. Szawan
Konrad A. Szawan
CTChristian Templin
Christian Templin

6 January 2026 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
CLChong Bin Lee
Chong Bin Lee
VSVictor Schweiger
Victor Schweiger
DSDaniel Schwarzkopf
Daniel Schwarzkopf
MKMarian Kukucka
Marian Kukucka
JKJoerg Kempfert
Joerg Kempfert
AUAxel Unbehaun
Axel Unbehaun
Objectives: Transcatheter mitral valve implantation (TMVI) is increasingly used in failed bioprostheses and annuloplasty rings as a less invasive alternative to redo-surgery in selected patients, with promising results. This retrospective single-centre study aims to provide additional insight into clinical outcomes and its determinants following TMVI. Methods: Data of all TMVI procedures (n = 88) performed between February 2014 and June 2024 were retrospectively analysed. The primary end-points were 1-year mortality and the Mitral Valve Academic Research Consortium (MVARC) composite end-points. Secondary outcomes included complications and echocardiographic outcomes. Results: Overall, in-hospital, 30-day, and 1-year mortality rates were 6.8%, 5.8%, and 16.5%, respectively. No significant differences were observed between transseptal and transapical approach (20.0 vs 13.2%, P = .439) or between valve-in-valve and valve-in-ring procedure (16.3 vs 18.2%, P = .828). At 1-year follow-up, only one patient presented with mitral regurgitation ≥ grade 2. However, a post-procedural mean pressure gradient (MPG) ≥5 mm Hg was observed in 51 patients (58%). In multivariate analysis, higher post-procedural MPG was associated with increased mortality risk (P = .047; hazard ratio [HR] = 1.23; 95% CI, 1.00-1.51), whereas technical success was associated with reduced mortality risk (P = .014; HR = 0.12; 95% CI, 0.02-0.65). Conclusions: Transcatheter mitral valve implantation provided acceptable mid-term mortality irrespective of procedure type and access route, with excellent technical success. Furthermore, mid-term follow-up showed near-complete elimination of mitral regurgitation. However, a high rate of post-procedural relevant mitral stenosis was observed, which may have an impact on mortality. In the light of the anticipated increase in TMVI procedures, we advocate for larger prospective studies to investigate the long-term determinants of mortality. Clinical trial registration: As this study was retrospective and based on previously collected clinical data, clinical trial registration was not required.

17 June 2026 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MMMichele Maremmani
Michele Maremmani
PGPaolo Gianfico
Paolo Gianfico
CTChristian Templin
Christian Templin
Fabrizio MontecuccoFabrizio Montecucco
Fabrizio Montecucco
LLLuca Liberale
Luca Liberale
DVDavide Di Vece
Davide Di Vece

29 June 2021
Verified
Dataset
Closed access
JHJakob Hirsch
Jakob Hirsch
FNFelix Nägele
Felix Nägele
LPLeo Pölzl
Leo Pölzl
MGMichael Graber
Michael Graber
MGMichael Grimm
Michael Grimm
JHJohannes Holfeld
Johannes Holfeld
This article describes a standardized murine model of tissue regeneration via shockwave treatment.